Company intelligence / Profile preview
Illuminare Biotechnologies
Brooklyn, New York, United Statesilluminarebio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Illuminare-1, the company's lead candidate, is currently in a first-in-human Phase 1 clinical trial at Memorial Sloan Kettering Cancer Center, focusing on radical prostatectomy to demonstrate safety and initial efficacy in improving nerve visualization. The IND was approved by the FDA in April 2021. The company expects to enter Phase 2 in 2025.[1][4][5]
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Memorial Sloan Kettering Cancer Center
Beyond the preview
Go deeper on Illuminare Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Illuminare Biotechnologies.